THE WHAT? The Brazilian Health Regulatory Agency (ANVISA) has approved the import of Khiron medical cannabis product, to be imported on an individual patent basis.
THE DETAILS The new framework set by ANVISA is said to set a ‘comprehensive procedure for the manufacture and import of medical cannabis products and requirements for commercialization, prescription and dispensing.’
THE WHY? The authorization gives Khiron the ability to expand its foothold on the Latin American market, and will enable it to apply for a permit in order to export its product from Colombia. According to the release, commercialisation in Brazil is also conditional on TSXV approval.
Alvaro Torres, Khiron CEO and Director, said, “Within our LatAm strategy receipt of this authorization from ANVISA represents another regulatory milestone in bringing our medical cannabis products to the largest patient market in Latin America. With a continued focus on the health and wellbeing of patients in the region, we continue to grow our network in Brazil as we also work towards pending authorizations in Colombia and Peru.”